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Abstract 
Background 
There is evidence of statin benefit among patients with diabetes regardless of cholesterol levels 
or prior cardiovascular disease history. Despite the evidence, there is under-prescription of 
statins in clinical practice. This study aimed to assess statin prescriptions and associated factors 
among patients with type 2 diabetes in Botswana.  
Methods 
The study was a secondary data analysis of 500 randomly selected type 2 diabetes patients at a 
specialised diabetes clinic at Gaborone, Botswana. We assessed the proportion of statin-eligible 
patients who are prescribed statins and evaluated the adjusted associations between various 
factors and statin prescriptions. 
Results 
Overall, 477 (95.4%) participants were eligible for a statin prescription. Clinicians prescribed 
statins in 217 (45.5%) of eligible participants, and only one (4.4%) ineligible participant. The 
probability of a statin prescription was higher in participants with high baseline low-density 
lipoprotein cholesterol (risk ratio [RR]: 1.49; 95%CI: 1.17-1.89), increasing duration of diabetes 
(RR: 1.01; 95%CI 1.00-1.03) and the presence of chronic kidney disease (RR: 1.35; 95%CI: 1.06-
1.74). 
Conclusion 
A large proportion with type 2 diabetes in Gaborone is not receiving statins. Clinicians did not 
consider most guideline-recommended indications for statin prescriptions. The findings call for 
improvement in diabetes quality of care by implementing evidence-based guideline 
recommendations.  
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Background 
Cardiovascular disease (CVD), which includes coronary artery disease (CAD), cerebrovascular 
accident (CVA), and peripheral arterial disease (PAD), is common and contributes to over two-
thirds of mortality among patients with type 2 diabetes mellitus [1-3]. While the presence of type 
2 diabetes alone confers the highest risk for CVD of any single risk factor, the coexistence of other 
cardiovascular risk factors is a common phenomenon [3, 4]. Consequently, guidelines advise 
screening and optimal treatment of CVD risk factors in patients with diabetes [5, 6]. Besides, 
prescribing of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins) among 
patients with type 2 diabetes reduces the risk of major CVD events by 23%-33% [7-9]. There is 
evidence of statin benefit among patients with diabetes regardless of their low-density 
lipoprotein cholesterol (LDL-C) values or prior CVD history [7, 9-14].  For each mmol/l reduction 
in LDL-C, there is evidence of a 9% relative reduction in all-cause mortality in patients with 
diabetes [15]. Irrespective of LDL-C, guidelines recommend statins for patients with diabetes 
aged ≥ 40 years without atherosclerotic cardiovascular disease (ASCVD), or those who are 
younger than 40 years but with existing ASCVD or additional risk factors [5, 6].  
While some studies in developed countries have reported high use of statins among patients 
with type 2 diabetes, there has generally been under-prescribing of statins across many countries 
[16-18]. Statin prescribing among patients with type 2 diabetes is as high as 100% in developed 
countries but as low as 3-13% in Africa [17-23]. The suboptimal utilisation of statin therapy in 
Africa is due to many factors, but mainly limited access to standard diabetes care because of the 
high cost of tests and medications with typically high co-payment levels [22]. Affordability is a 
critical issue in several African countries where there is no universal healthcare, with the cost of 
medicines accounting for up to 70% of total healthcare expenditure, much of which is out-of-
pocket [24, 25]. Statin under-prescribing is a concern given the high growth rates of 
cardiovascular diseases in sub-Saharan African countries and current poor control of 
cardiovascular diseases [26-31]. The underuse of statins significantly increases the incidence of 
cardiovascular events and associated mortality [32]. Although healthcare is free in Botswana, 
factors not related to cost may still affect the uptake of statins in patients with diabetes. This is 
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problematic given current prevalence rates of diabetes in Botswana and the resultant impact on 
morbidity and mortality [33-36]. Published data on the impact of diabetes mellitus on CVD  in 
Botswana are scant. About a quarter of patients admitted with heart failure had type 2 diabetes 
in a recent study in Gaborone [34]. Although data on atherosclerotic diseases in Botswana are 
missing, we can expect that diabetes-related coronary atherosclerosis underlines some cases of 
heart failure  [34, 36]. In addition, the rising burden and suboptimal control of CVD risk factors in 
patients with type 2 diabetes have become an increasing concern in Botswana [37]. One of the 
critical steps that will prevent or slow ASCVD in this suboptimally-treated patients is the use of 
statins [5]. Currently, there is no study assessing the extent of statin prescriptions among patients 
with type 2 diabetes in Botswana. We aimed to address this by evaluating the extent of statin 
prescription among patients with type 2 diabetes in Botswana. Our secondary aim was to 
determine factors associated with statin prescription among type 2 diabetes.  
Methods 
Study design  
We conducted a secondary analysis of data from a previous study among type 2 diabetics at a 
specialised diabetes clinic in Gaborone, Botswana. Any concerns with the management of 
diabetic patients in this dedicated clinic are likely to be exacerbated in non-specialist centres such 
as primary healthcare centres.  
Participant recruitment and data collection 
The original study took place between August 2017 and February 2018 [37]. The primary 
objective of the original study was to assess glycaemic, low-density lipoprotein, and hypertension 
control in patients with type 2 diabetes. The study included 500 randomly selected patients with 
type 2 diabetes aged ≥ 18 years, attending the clinic for at least three months before data 
collection.  Using systematic random sampling, we enrolled every eighth patient from the daily 
lists of patients attending the clinic. The enrolment occurred in the mornings and afternoons until 
either the daily target of ten patients was achieved or the end of clinic consultations. 
Demographic data (age, sex, occupation, educational attainment, and marital status), duration 
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of diabetes, and the type of diabetes medications were collected. Other information was the 
history of hypertension, lipid disorders, ischemic heart diseases, stroke or peripheral vascular 
disease. We also recorded data on the use of medications for hypertension and lipid disorders 
(including statins), and anthropometric measurements (weight, height, hip and waist 
circumferences). With participants in light clothing and without footwear,  we measured 
participants’ height and weight to the nearest 0.1 centimetres (cm) and 0.1 kilograms (kg) 
respectively [38]. We also measured the hip and waist circumferences (to the nearest 0.1cm   a 
non-stretchable tape measure at a hip and level midway between the lowest rib and iliac crest 
[39]. After 10 minutes of rest, three seated blood pressure (BP) measurements were taken from 
the right arm using a digital automatic BP monitor (Omron) [38, 40]. We documented the average 
of the three readings and that of each patient’s previous visit. In addition, we used the electronic 
medical records to obtain participants’ serum creatinine and low-density lipoprotein-cholesterol 
(LDL-C), and urine dipsticks for proteinuria results within six months of enrolment [37]. The 
diabetes clinic has a satellite laboratory that performs tests per protocol as defined by the ISO-
9000 certified Princess Marina Hospital clinical laboratory. Total cholesterol (TC), triglycerides 
(TG) and high-density lipoprotein cholesterol (HDL-C) are measured enzymatically in plasma using 
commercial kits made by Roche Diagnostics, Switzerland. LDL-cholesterol was calculated using 
the Friedwald formula as TC-HDL-C-TG/2.2 in mmol/dL [41]. For the present study, we evaluated 
the extent of statin prescriptions among the participants. The primary outcome measure was 
receiving a statin prescription among statin-eligible participants. We assessed statin eligibility 
based on the Society for Endocrinology, Metabolism, and Diabetes of South Africa (SEMDSA) 
guidelines [6].  According to SEMDSA, the eligibility for statin prescribing included any CVD or 
chronic kidney disease (CKD),  age above 40 years, and diabetes duration longer than ten years. 
In addition, a statin prescription is indicated in the presence of one or more of the following 
cardiovascular risk factors;  hypertension, cigarette smoker,  HDL-C level, family history of early 
CAD, and any albuminuria  [6]. Other independent variables included baseline serum LDL-C, body 
mass index (BMI), waist-hip ratio (WHR) and level of education.  
  
6 
 
Definition of terms 
The diagnosis of hypertension based on the self-reported history of hypertension, the use of 
hypertension-lowering medications or sustained blood pressure ≥140/90 mmHg in more than 
one visit [42]. We defined CVD as the history of CAD,  CVA (ischemic stroke, transient ischemic 
attacks), or PAD [6]. CAD was any documented definite or probable myocardial infarction, CAD-
related revascularisation (surgery, angioplasty, stenting, or any combination of these), or stable 
angina in participants’ medical records [43]. Data on CVA and PDA were extracted from 
participants’ medical records as defined by the treating physician. Smoking status was a 
documented self-report of current smoking habits. We estimated glomerular filtration rate 
(eGFR) using the Modification of Diet in Renal Disease(MDRD), and classified patients with eGFR 
< 60ml/minute/1.73m2 as having CKD [44]. BMI was categorized into underweight for BMI <18.5 
kg/m2; normal for BMI of 18.5 – 24.9 kg/m2 , overweight for 25.0–29.9 kg/m2; or obese for BMI 
≥30 kg/m2 [45]. We also calculated the WHR by dividing waist circumference (cm) by hip 
circumference (cm) and defined WHR ≥ 0.85 for women and ≥ 0.90 for men as high[39]. Dipstick 
proteinuria appeared as negative (−), trace, (+), (++), or (+++) in the dataset. We classified 
proteinuria in individuals with  ≥ (+) dipstick proteinuria results. For patients already on lipid-
lowering medications and whose baseline 'untreated' levels of lipid profile were not available, 
we estimated the LDL-C levels before the initiation of statin treatment as in previous studies [46]. 
The adjustment was made based on the assumption that most patients received atorvastatin (the 
only statin available in the public sector in Botswana) at a dosage of at least 10mg per day and 
an overall adherence of 60 % [47]. We calculated the baseline LDL-C levels by assuming that the 
measured LDL-C is a result of a 25% reduction from baseline [46]. Baseline LDL-C levels above 
4.13 mmol/l were considered high [48]. 
Statistical analysis 
Clean data were imported from MS Excel and analysed using Stata Version 14 (Stata Corp, College 
Station, TX). Categorical variables were presented as frequencies and percentages, and 
continuous variables as mean (standard deviation [SD]) or medians [first–third quartiles]. 
Comparison of clinical and demographic factors by gender and statin use was achieved by using 
the Chi-square or Fisher’s exact tests for categorical variables, and independent student’s t-tests 
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or Wilcoxon rank-sum test for continuous variables as appropriate. A 2-sided p-value < 0.05 was 
considered as statistically significant. As the outcome of interest (a statin prescription) was a 
common event, and our study design was cross-sectional, we estimated relative risks (RRs) as 
measures of association. Log-binomial models or generalised linear models for the binomial 
family were fitted to assess for independent predictors for statin prescribing. The multivariable 
model included all factors with p < 0.2 on bivariate analysis. We used a backward selection 
modelling method with probabilities set at 0.05 and 0.1 for inclusion and exclusion; respectively. 
We report adjusted risk ratios (RRs), 95% confidence intervals (CIs), and p-values.  With a sample 
size of 477 statin-eligible participants,  we were able to estimate the prevalence of statin use of  
13%  with a margin of error of 3% on a two-sided alpha level of 0.05 [22].  
Results 
There were 500 participants in the dataset, with a mean (SD) age of 58.9 (12.2) years and 330 
(66%) were females. Table 1 summarises baseline participants’ characteristics by gender. The 
majority (96.7%) of participants aged ≥ 40 years and women were significantly older than men. 
Approximately a third (34.4%) of participants had a diabetes duration of over ten years. 
Hypertension (84.7%) and obesity (51.6%) were prevalent, especially in female participants. 
Overall, CKD (11.3%), proteinuria (10.7%), CVD (8.8%), and smoking (3.4%) were uncommon. The 
mean (SD) baseline LDL-C was 3.1 (1.2) mmol/L, and significantly higher in female than male 
participants. 
[Table 1: Demographic and clinical characteristics of patients with type 2 diabetes at a 
specialised Diabetes clinic in Gaborone (N=477)] 
 
Statin eligibility and prescribing rates 
Of the 500 participants, 477 (95.4%) were eligible for a statin prescription. Clinicians prescribed 
statins (exclusively atorvastatin) in 217 (45.5%) of statin-eligible participants, and only one (4.4%) 
ineligible participant. Seven (1.5%) participants received prescriptions of other lipid-lowering 
medications alone or in combination with statins.  Of those who were eligible for statins, statin-
prescribed individuals differed from those without prescriptions in several parameters on the 
bivariate analysis (Table 2). Relative to the statin-non-prescribed group, the statin-prescribed 
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group had a longer duration of diabetes (8.9 years vs. 6.0 years; p < 0.001); were older (61.5 years  
vs 59.2 years ; p = 0.018), more likely to be hypertensive (85.7% vs 78.1% ; p< 0.032),  more likely 
to have CKD (17.2% vs 6.6%;  p= 0.001), and a higher baseline LDL-C ( 3.3 vs 2.9 mmol/L;  p 
<0.001). The two groups did not differ significantly in the presence of CVD, proteinuria and 
gender. 
[Table 2: Factors associated with statin prescription among statin-eligible patients with type 2 
diabetes at a specialised Diabetes clinic in Gaborone (N= 477)] 
Multivariable analysis 
The multivariable log-binomial model examined adjusted associations between statin 
prescription and various factors. The best fit had the following covariates: age, the duration of 
diabetes, BMI, hypertension, a high baseline LDL-C, CKD, CVD, and proteinuria. Increasing 
diabetes duration was associated with an increased likelihood (RR: 1.01; 95%CI 1.00-1.03) of 
receiving a statin prescription (Table 3). The presence of CKD (RR: 1.35; 95%CI: 1.06-1.74) and a 
high baseline LDL-C (RR: 1.49; 95%CI: 1.17-1.89)  were also associated with an increased 
likelihood of a statin prescription. Age, BMI, history of CVD, and a diagnosis of hypertension were 
not associated with statin prescribing after adjustment for the other variables in the model. 
[Table 3 Adjusted relative risks for associations between various factors and statin prescription 
among statin eligible patients with diabetes at a specialised diabetes clinic in Botswana]  
Discussion  
Less than half of the statin-eligible patients with type 2 diabetes at a specialised diabetes clinic 
in Botswana received a statin prescription. A longer duration of diabetes, a higher baseline LDL-
C and the presence of chronic kidney disease were independently associated with the tendency 
to prescribe statins. 
The under-prescription of statins in this population is a concern since the use of statins 
appreciably reduces cardiovascular morbidity and mortality in patients with diabetes irrespective 
of their LDL-C levels [7, 9-13]. Whilst the proportion of patients with diabetes who are prescribed 
statins varies substantially worldwide; there is a low prescribing of statins both in developing and 
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developed countries [18, 19, 21-23, 49-52]. Encouragingly, the percentage of patients with 
diabetes who received statins (45.5%) in our study appears appreciably higher than the 3-13% 
seen in some African countries and consistent with findings from developed countries where 
between 25% to 73% of patients with diabetes are prescribed statins [18, 19, 22, 49-51]. The 
proportion of statin prescription in this population is higher than has been reported in some 
developed countries, including Germany (25%) and the United Kingdom (33%)[18, 49]. While the 
finding of a comparatively higher statin prescription in this setting than some African countries 
and some developed countries is encouraging, there is no reason for complacency as more than 
half of our patients were without CVD protection by statins. Similar to developed countries, one 
potential explanation for low statin prescribing rates among our patients with diabetes is 
inadequate adherence to guidelines [22, 52-54]. Whereas there may be a fear of the association 
of statin therapy with a slightly increased risk of developing diabetes, the benefits of statins in 
reducing cardiovascular morbidity and mortality among patients with established diabetes 
should dispel these concerns [7-9, 55]. As mentioned, several epidemiological studies have 
observed a lower proportion of statin prescribing in patients with diabetes in Africa than in this 
population [21-23]. In addition to inadequate adherence to guidelines, the main reasons for low 
statin prescribing in Africa include limited access to these medicines due to their high cost with 
high co-payment levels,  inaccessibility to lipid testing facilities and unavailability of guidelines 
[22]. The presence of free consultations, tests and medications in Botswana might explain our 
higher statin prescribing rates than those seen in other African settings without universal health 
access.  Irrespective of the reasons, it is imperative that statins are routinely prescribed to reduce 
the risk of CVD events in patients with type 2 diabetes [7-13, 15, 56].  
Our results of increasing statin prescribing with increasing diabetes duration also agree with 
previous research findings [57]. This finding is reassuring as a longer duration of diabetes leads 
to an increased risk of CVD. For this reason, guidelines recommend statins for patients with 
diabetes for more than ten years [5, 6]. Although the median diabetes duration was seven years 
in our participants, the association between statin prescribing and diabetes duration was still 
apparent. The finding may suggest that clinicians correctly recognise a longer duration of 
diabetes as an indication for statin therapy. As it may take time for the transmission of 
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information between clinicians and patients, the acceptance of new medications is likely easier 
as the diabetes duration increases [58]. 
Another finding in our study was that the presence of CKD increased the likelihood of statin 
prescribing. This finding is also encouraging as statins reduce mortality by up to 36% in patients 
with kidney failure [5, 6, 59, 60]. The finding is also consistent with SEMDSA guideline 
recommendations of a statin for every patient with diabetes and CKD [6]. While albuminuria is a  
marker of renal disease, participants with proteinuria did not receive  statin prescriptions. We 
can postulate that clinicians do not recognise proteinuria as a predictor of CVD and an indication 
for statins in patients with diabetes. This finding warrants further investigation as it is in contrast 
with Berthold et al., who reported increased odds of statin prescribing in type 2 diabetes patients 
with proteinuria in Germany [18]. 
Our findings that a high baseline LDL-C increased the likelihood of statin prescribing agreed with 
those of Berthold at al. that showed an 11% increase in statin prescribing rates for every 0.26 
mmol/L increase in LDL-C [18]. This finding also confirms the observation from previous studies 
that prescribers tend to respond more to the pre-treatment LDL-C value than to the patients’ 
overall CVD risk profile as described in clinical guidelines [9, 53]. Although there is a lack of local 
guidelines, our diabetes clinic adopted the SEMDSA guidelines which recommend statins along 
with lifestyle changes regardless of cholesterol levels for all patients with diabetes aged > 40 with 
or without CVD[6]. Our findings that statin prescription was based on LDL-C level may suggest a 
need for deliberate efforts for improving the understanding and implementation of the adopted 
guidelines, and we will be taking this further. 
In most clinical guidelines, the presence of CVD, CKD, patients age, diabetes and presence of CVD 
risk factors such as hypertension, albuminuria and cigarette smoking are indicators of prescribing 
statins among patients with type 2 diabetes[5, 6]. The presence of any of the above factors is 
associated with an increased risk of CVD. Except for CKD and duration of diabetes, none of the 
other indications was a predictor of statin prescriptions in this population. Given the high 
prevalence of hypertension and other indications in this population, most participants would 
have qualified for statins if guideline recommendations were followed. As our clinic has adopted 
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the SEMDSA guidelines, this finding is a concern and a call for efforts to improve its 
implementation for the benefit of this high-risk population.  
We are aware of a number of limitations of our study. We estimated the baseline LDL-C levels by 
a 25% adjustment of measured LDL. There was a risk of either overestimation or underestimation 
of the baseline LDL-C due to possible errors in our assumptions of the dosage and adherence of 
atorvastatin. Although measured LDL-C results were available for most of the included 
participants, HDL cholesterol results were mostly missing. Guidelines consider HDL as one of the 
factors for statin prescribing in patients with diabetes. However, data for all other indications for 
statin prescribing were available in dataset. We did not document the dosage of statin used in 
our patients; hence, we are unable to determine whether moderate to high-intensity statins were 
prescribed as recommended by the guidelines. In addition, we were unable to identify patients 
with contraindications to warfarin as the information was not available. The study was also 
performed in one clinic, hence limiting the generalizability of the study findings to other facilities 
in the country. However, being one of the few specialised diabetes clinics in  Botswana, our 
results likely characterise the ‘finest’ diabetes care in the country.  Consequently, the highlighted 
concerns are likely to be greater in non-specialist healthcare facilities treating patients with type 
2 diabetes in Botswana. 
Conclusion  
In conclusion, we believe this study provides a useful and reliable picture of current statin 
prescribing behaviour in Botswana despite the limitations. There is appreciable under-prescribing 
of statins in this high-risk population. The presence of CKD, high baseline LDL, and an increased 
duration of diabetes strongly influenced statin prescriptions in patients with diabetes. Clinicians 
did not consider most guideline-recommended indications for the prescribing of statins. By 
identifying gaps in the prescription of statins to patients with diabetes, the study provides an 
opportunity for improvement in the quality of care. Furthermore, the study findings suggest a 
need for further studies to investigate the reasons for statin under-prescription in our setting. 
We are following this up to provide future guidance for clinicians in Botswana treating patients 
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with type 2 diabetes, with the results likely to be of interest to other sub-Saharan African 
countries with high rates of type 2 diabetes. 
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Table 1: Demographic and clinical characteristics of patients with type 2 diabetes at a 
specialised Diabetes clinic in Gaborone (N= 477)  
Characteristics 
All (N=477) Males (n= 160) Females (n= 317) 
Age, mean(SD), years 60.3(10.8) 56.8(11.5) 62.0(10.1) 
Age > 40 years n(%) 461(96.7) 150(93.8) 311(98.1) 
Diabetes duration, median, IQR, years 7(3-13) 8.9(3-14) 7 (3-13) 
Diabetes duration > 10 years 164 (34.4) 63(39.4) 101(31.9) 
BMI, mean (SD) kg/m2 30.7(6.0) 29.0(5.2) 31.6(6.1) 
 Normal weight n(%) 85(17.8) 39(24.4) 46(14.5) 
 Overweight n(%) 146(30.6) 59(36.7) 87(27.4) 
 Obese n(%) 246(51.6) 62(38.8) 184(58.0) 
Marital status    
 Living alone n(%) 247(51.8) 47(29.4) 200(63.1) 
 Living with a partner n(%) 230(48.2) 113(70.6) 117(36.9) 
Education status    
 ≤ Primary education, n(%) 306(64.1) 82(51.3) 224(70.7) 
 ≥ Secondary or tertiary, n(%) 171(35.9) 78(48.7) 93(29.3) 
WHR, mean (SD) 0.94(0.10) 0.97(0.08) 0.93(0.09) 
 Low WHR n (%) 79(16.6) 67(41.9) 12(3.8) 
 High WHR n (%) 398(83.4) 93(58.1) 305(96.2) 
Hypertension n (%) 404(84.7) 120(75.0) 284(89.6) 
Use of antihypertensive n (%) 389(81.6) 110(68.8) 279(88.0) 
Smoking n (%) 16(3.4) 12(7.5) 4(1.3) 
Lipid-lowering medications n (%) 224(47.0) 70(43.8) 154(48.6) 
 Statins n (%) 217(45.5) 68(42.5) 149(47.0) 
 Others n (%) 7(1.5) 2(1.6) 5(1.6) 
CVD n (%) 42(8.8) 15(9.4) 27(8.5) 
 PAD n (%) 11(2.3) 3(1.9) 8(2.5) 
 Coronary artery disease n (%) 12(2.5) 5(3.3) 7(2.2) 
 Cerebrovascular disease n (%) 22(4.6) 8(5.0) 14(4.4) 
CKD n (%) 54(11.3) 24(15.0) 30(9.5) 
Proteinuria n (%) 51(10.7) 27(16.9) 24(7.6) 
HbA1c mean (SD), % 8.4(2.4) 8.5(2.6) 8.3(2.3) 
Baseline LDL-C, mean (SD), mmol/L 3.1(1.2) 2.8(1.1) 3.3(1.2) 
 Normal 315(66.0) 113(70.6) 202(63.7) 
 High 59(12.4) 9(5.6) 50(15.8) 
 Missing  103(21.6) 38(23.8) 65(20.5) 
Legend: BMI: Body Mass Index, CKD : chronic kidney disease, CVD : cardiovascular disease, HbA1c : Haemoglobin A1c, IQR : 
interquartile range; LDL-C : low-density lipoprotein cholesterol, PAD : peripheral artery disease, SD : standard deviation; WHR : 
waist-hip ratio. 
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Table 2: Factors associated with statin prescription among statin-eligible patients with type 2 
diabetes at a specialised Diabetes clinic in Gaborone (N= 477) 
Characteristics 
Statin not prescribed (n= 
260) 
Statin prescribed 
(n= 217) 
P-value 
Sex    
 Males, n (%) 92(35.4) 68(31.3) 
0.351 
 Female, n (%) 168(64.6) 149(68.7) 
Diabetes duration, median, IQR, 
years 
6(2 – 12) 8.9(4 – 15) <0.001 
 Duration ≤ 10 years 179(68.9) 134(61.8) 
0.104 
 Diabetes duration > 10 years 81(31.1) 83(38.2) 
Age, mean (SD), years 59.2(10.8) 61.5(10.7) 0.018 
 Age ≤ 40 years, n (%) 12(4.6) 4(1.8) 
<0.094 
 Age > 40 years n (%) 248(95.4) 213(98.2) 
Marital status    
 Living alone n (%) 135(51.9) 112(51.6) 
0.946 
 Living with a partner n (%) 125(48.1) 105 (48.4) 
Education status    
 ≤ Primary education, n (%) 166(63.9) 140(64.2) 
0.879 
 ≥ Secondary or tertiary, n (%) 94(36.1) 77(35.8) 
Hypertension n (%) 212(81.5) 192 (88.5) 0.036 
Antihypertensive use n (%) 203(78.1) 186(85.7) 0.032 
Smoking 13(5.0) 3(1.4) 0.029 
CVD, n (%) 20(7.7) 22(10.1) 0.538 
 PAD, n (%) 7(2.7) 4(1.8) 0.625 
 Coronary artery disease n (%) 6(2.3) 6(2.8) 0.751 
 Cerebrovascular diseases n (%) 9(3.5) 13(6.0) 0.190 
BMI, mean (SD) kg/m2 30.3(5.7) 31.2(6.2) 0.113 
 Normal weight n (%) 50(19.2) 35(16.1) 
0.669  Overweight n (%) 79(30.4) 67(30.9) 
 Obese n (%) 135(47.9) 115(52.8) 
WHR, mean (SD) kg/m2 0.94(0.08) 0.95(0.10) 0.106 
 Low WHR n (%) 46(17.7) 33(15.2) 
0.467 
 High WHR n (%) 214(82.3) 184(84.8) 
CKD, n (%) 20(7.7) 34 (15.7) 0.006 
Proteinuria, n (%) 30 (11.5) 21(9.7) 0.512 
HbA1c mean (SD), % 8.4(2.6) 8.4(2.2) 0.948 
Baseline LDL-C mean (SD), mmol/L 2.9(0.9) 3.3(1.4) 0.003 
 Normal 177(68.1) 120(55.3) 
<0.001 
 High  17(6.5) 42(19.4) 
 Missing 66(25.4) 55(25.3)  
Legend: BMI : Body Mass Index; CKD : chronic kidney disease; CVD : cardiovascular disease; HbA1c : 
Haemoglobin A1c;  IQR : interquartile range; LDL-C : low-density lipoprotein cholesterol; PAD : 
peripheral artery disease; SD : standard deviation; WHR : waist-hip ratio. 
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Table 3 Adjusted relative risks for associations between various factors and statin prescription 
among statin eligible patients with diabetes at a specialised diabetes clinic in Botswana  
Characteristic Risk ratio 95% Conf. Interval p-value 
Age 1.006 0.994-1.017 0.362 
CKD 1.354 1.055-1.738 0.017 
Hypertension 1.336 0.846-2.110 0.213 
BMI 1.014 0.994-1.034 0.16 
High baseline LDL 1.488 1.173-1.887 0.001 
Diabetes duration, years 1.014 1.000-1.027 0.048 
Proteinuria 0.979 0.644-1.488 0.922 
CVD 0.901 0.623-1.303 0.581 
Legend: BMI : Body Mass Index, CKD : chronic kidney disease, CVD : cardiovascular disease, LDL-C : low-
density lipoprotein cholesterol. 
